Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?

@article{Milano2000CanDD,
  title={Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?},
  author={G{\'e}rard A. Milano and Howard L. McLeod},
  journal={European journal of cancer},
  year={2000},
  volume={36 1},
  pages={
          37-42
        }
}
  • Gérard A. Milano, Howard L. McLeod
  • Published in European journal of cancer 2000
  • Medicine
  • More than 80% of an administered 5-fluorouracil (5-FU) dose is degraded by dihydropyrimidine dehydrogenase (DPD), making it an important regulator of this commonly used anticancer agent. The high variation in population DPD activity, association with 5-FU activity, and development of DPD inhibitors have all contributed to the current focus on this enzyme. This review details the impact of DPD on 5-FU pharmacology, catalogues recent information on DPD mutations, evaluates the case for tumour DPD… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 36 CITATIONS

    Pharmacogenomics of fluorouracil -based chemotherapy toxicity.

    VIEW 6 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population

    VIEW 7 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    Past and Future Directions

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Pharmacogenomics: unlocking the human genome for better drug therapy.

    VIEW 6 EXCERPTS
    CITES RESULTS & BACKGROUND

    [Postoperative radiation therapy for a patient with osteogenesis imperfecta: case report].